{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:55Z","timestamp":1786982395115,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ADHD Atten Def Hyp Disord"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s12402-009-0012-4","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T04:17:03Z","timestamp":1253593023000},"page":"201-210","source":"Crossref","is-referenced-by-count":22,"title":["Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder"],"prefix":"10.1007","volume":"1","author":[{"given":"Philip","family":"Hazell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eija A.","family":"Nikkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula T.","family":"Trzepacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Tabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah N.","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Witcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ponsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf W.","family":"Dittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,23]]},"reference":[{"issue":"2","key":"12_CR1","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1542\/peds.2006-1880","volume":"121","author":"ME Bangs","year":"2008","unstructured":"Bangs ME, Hazell P, Danckaerts M et al (2008) Atomoxetine for the treatment of attention-deficit\/hyperactivity disorder and oppositional defiant disorder. Pediatrics 121(2):e314\u2013e320","journal-title":"Pediatrics"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/sj.npp.1300839","volume":"30","author":"MA Bellgrove","year":"2005","unstructured":"Bellgrove MA, Hawi Z, Kirley A et al (2005) Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit\/hyperactivity disorder. Neuropsychopharmacology 30:2290\u20132297","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"12_CR3","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.1542\/peds.107.3.e43","volume":"107","author":"RT Brown","year":"2001","unstructured":"Brown RT, Freeman WS, Perrin JM et al (2001) Prevalence and assessment of attention-deficit\/hyperactivity disorder in primary care settings. Pediatrics 107(3):E43","journal-title":"Pediatrics"},{"issue":"6","key":"12_CR4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/01.chi.0000120019.48166.1e","volume":"43","author":"DAG Drabick","year":"2004","unstructured":"Drabick DAG, Gadow KD, Carlson GA et al (2004) ODD and ADHD symptoms in Ukrainian children: external validators and comorbidity. J Am Acad Child Adolesc Psychiatr 43(6):735\u2013743","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"issue":"2","key":"12_CR5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1469-7610.00012","volume":"43","author":"KD Gadow","year":"2002","unstructured":"Gadow KD, Nolan EE (2002) Differences between preschool children with ODD, ADHD, and ODD\u00a0+\u00a0ADHD symptoms. J Child Psychol Psychiatr 43(2):191\u2013201","journal-title":"J Child Psychol Psychiatr"},{"issue":"14","key":"12_CR6","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jama.279.14.1100","volume":"279","author":"LS Goldman","year":"1998","unstructured":"Goldman LS, Genel M, Bezman RJ et al (1998) Diagnosis and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Council on scientific affairs, American Medical Association. JAMA 279(14):1100\u20131107","journal-title":"JAMA"},{"key":"12_CR7","doi-asserted-by":"crossref","unstructured":"Guy W (1976) ECDEU Assessment manual for psychopharmacology, revised. Publication ADM 76-338. United States Department of Health, Education, and Welfare, Bethesda, Md","DOI":"10.1037\/e591322011-001"},{"issue":"7","key":"12_CR8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","volume":"36","author":"J Kaufman","year":"1997","unstructured":"Kaufman J, Birmaher B, Brent D et al (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatr 36(7):980\u2013988","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"issue":"9","key":"12_CR9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/chi.0b013e318074eeb3","volume":"46","author":"CJ Kratochvil","year":"2007","unstructured":"Kratochvil CJ, Michelson D, Newcorn JH et al (2007) High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatr 46(9):1128\u20131375","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"issue":"12","key":"12_CR10","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/00004583-199712000-00020","volume":"36","author":"M Kuhne","year":"1997","unstructured":"Kuhne M, Schachar R, Tannock R (1997) Impact of comorbid oppositional or conduct problems on attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatr 36(12):1715\u20131725","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"issue":"2","key":"12_CR11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/01.chi.0000246056.83791.b6","volume":"46","author":"D Michelson","year":"2007","unstructured":"Michelson D, Read HA, Ruff DD et al (2007) CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatr 46(2):242\u2013251","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"12_CR12","first-page":"839","volume":"21","author":"National Institute of Mental Health","year":"1985","unstructured":"National Institute of Mental Health (1985) Clinical global impressions. Psychopharmacol Bull 21:839\u2013843","journal-title":"Psychopharmacol Bull"},{"key":"12_CR13","unstructured":"Newcorn H, Zhang S, Rogers AK et al (2007) Atomoxetine treatment response in ADHD patients na\u00efve to previous pharmacotherapy. Presented at the 13th international congress of the european society for child and adolescent psychiatry (ESCAP), August 25\u201329, 2007, Florence, Italy"},{"issue":"2","key":"12_CR14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S1461145707008115","volume":"11","author":"M Paulzen","year":"2008","unstructured":"Paulzen M, Clement HW, Gr\u00fcnder G (2008) Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol 11(2):289\u2013291. Epub 2007 Sep 28","journal-title":"Int J Neuropsychopharmacol"},{"key":"12_CR15","unstructured":"Poznanski EO, Mokros HB (1996) Children\u2019s depression rating scale, revised (CDRS-R) manual. Western Psychological Services, Los Angeles"},{"issue":"6","key":"12_CR16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2165\/00003088-200544060-00002","volume":"44","author":"JM Sauer","year":"2005","unstructured":"Sauer JM, Ring BJ, Witcher JW (2005) Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44(6):571\u2013590","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"12_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-006-0483-3","volume":"188","author":"N Seneca","year":"2006","unstructured":"Seneca N, Guly\u00e1s B, Varrone A et al (2006) Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S, S)-[18F]FMeNER-D2. Psychopharmacology (Berl) 188(1):119\u2013127","journal-title":"Psychopharmacology (Berl)"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00004583-200102000-00011","volume":"40","author":"JM Swanson","year":"2001","unstructured":"Swanson JM, Kraemer HC, Hinshaw SP et al (2001) Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatr 40:168\u2013179","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"issue":"4","key":"12_CR19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/cap.2006.16.416","volume":"16","author":"MH Teicher","year":"2006","unstructured":"Teicher MH, Polcari A, Foley M et al (2006) Methylphenidate blood levels and therapeutic response in children with attention-deficit\/hyperactivity disorder I. Effects of different dosing regimens. J Child Adolesc Psychopharmacol 16(4):416\u2013431","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"12_CR20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euroneuro.2007.06.002","volume":"18","author":"PT Trzepacz","year":"2008","unstructured":"Trzepacz PT, Williams DW, Feldman PD et al (2008) CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol 18(2):79\u201386","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["ADHD Attention Deficit and Hyperactivity Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12402-009-0012-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:23:56Z","timestamp":1558538636000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12402-009-0012-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,23]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s12402-009-0012-4","relation":{},"ISSN":["1866-6116","1866-6647"],"issn-type":[{"value":"1866-6116","type":"print"},{"value":"1866-6647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,23]]}}}